A photo of Nat Nasomyont.

Nat Nasomyont, MD, MS

  • Assistant Professor, UC Department of Pediatrics
My philosophy is to provide compassionate and personalized care. I like to engage children and their parents in developing the best treatment plan for them.

About

Biography

As a pediatric endocrinologist, I provide comprehensive care for children and adolescents with hormone disorders, including growth and puberty problems, thyroid diseases and diabetes. I also evaluate and treat metabolic bone diseases and osteoporosis in childhood and adolescents.

My philosophy is to provide compassionate and personalized care. I like to engage children and their parents in developing the best treatment plan for them. I am board certified by the American Board of Pediatrics (2017) and Pediatric Endocrinology (2021). As a Certified Clinical Densitometrist (2020), I also provide service in bone density analysis as part of a comprehensive bone health evaluation.

My current research focuses on bone health in children and adolescents with conditions that may predispose them to a compromised peak bone mass. Childhood and adolescence are critical periods for bone mass accrual. I hope my work on the early identification and intervention for children at risk for low bone mass will ultimately prevent osteoporosis during their adult years.

MD: Siriraj Hospital Faculty of Medicine, Bangkok, Thailand, 2011.

Residency: Pediatrics, University of South Alabama, Mobile, AL, 2017.

Fellowship: Pediatric Endocrinology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2020.

MS: Clinical and Translational Research, University of Cincinnati, Cincinnati, OH, 2020.

Certification: American Board of Pediatrics, 2017; Pediatric Endocrinology, 2021; Certified Clinical Densitometrist (CCD), 2020.

Interests

Pediatric endocrinology; metabolic bone disease; pediatric osteoporosis; diabetes

Services and Specialties

Endocrinology

Interests

Metabolic bone disease; pediatric osteoporosis

Research Areas

Endocrinology

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information

Publications

Selected

Outcomes following intravenous bisphosphonate infusion in pediatric patients: A 7-year retrospective chart review. Nasomyont, N; Hornung, LN; Gordon, CM; Wasserman, H. Bone. 2019; 121:60-67.

Elevated Bone Turnover Markers Predict Bone Mineral Density Accrual in Adolescents with 21-hydroxylase Deficiency. Wiromrat, P; Namphaisan, P; Wongsurawat, N; Panamonta, O; Nasomyont, N. Clinical Endocrinology. 2022.

Changes in Bone Marrow Adipose Tissue in Transgender and Gender Non-Conforming Youth Undergoing Pubertal Suppression: A Pilot Study. Nasomyont, N; Meisman, AR; Ecklund, K; Vajapeyam, S; Cecil, KM; Tkach, JA; Altaye, M; Corathers, SD; Conard, LA; Kalkwarf, HJ; et al. Journal of Clinical Densitometry. 2022.

The effect of oral bisphosphonate therapy on vertebral morphometry and fractures in patients with Duchenne muscular dystrophy and glucocorticoid-induced osteoporosis. Nasomyont, N; Tian, C; Hornung, L; Khoury, J; Hochwalt, PM; Tilden, JC; Wong, BL; Rutter, MM. Muscle and Nerve. 2021; 64:710-716.

Chapter 37 Osteoporosis in childhood and adolescence. Nasomyont, N; Gordon, CM. Marcus and Feldman's Osteoporosis. 2021.

Safety and efficacy of teriparatide treatment for severe osteoporosis in patients with Duchenne muscular dystrophy. Nasomyont, N; Keefe, C; Tian, C; Hornung, L; Khoury, J; Tilden, JC; Hochwalt, P; Jackson, E; Rybalsky, I; Wong, BL; et al. Osteoporosis International. 2020; 31:2449-2459.

Intravenous bisphosphonate therapy in children with spinal muscular atrophy. Nasomyont, N; Hornung, LN; Wasserman, H. Osteoporosis International. 2020; 31:995-1000.

Central diabetes insipidus in a patient with NFKB2 mutation: Expanding the endocrine phenotype in DAVID syndrome. Nasomyont, N; Lindsley, AW; Assa'ad, A; Dawson, DB; Neilson, DE; Brady, CC; Rutter, MM. Journal of Clinical Endocrinology and Metabolism. 2019.

SAT-LB052 Intravenous Bisphosphonate Therapy in Children with Spinal Muscular Atrophy. Nasomyont, N; Hornung, L; Wasserman, H. Journal of the Endocrine Society. 2019; 3:sat-lb052.

Growth Hormone Therapy for Turner Syndrome. Blunden, C; Nasomyont, N; Backeljauw, P. Pediatric Endocrinology Reviews. 2018; 16:80-90.

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey